THOUSAND OAKS,
Calif. and SAN DIEGO, June 27,
2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Piper
Jordan, one of the nation's leading health and benefits consulting
firms, today announced a unique partnership to help improve health
and well-being in the workplace for people living with migraine.
The collaboration aims to provide disease management resources to
both the employee and employer through innovative educational
programs, including well-being initiatives for those living with
migraine. This marks the first Amgen partnership with an employee
benefit consultant (EBC) and is Amgen's first migraine-specific
project with employers.
The burden of migraine has been under-recognized, despite the
fact that American employers lose an estimated $11 billion each year, largely due to missed work
days and lost productivity.1 In fact, in a recent global
migraine patient survey, employed respondents in the U.S. reported
they felt a lack of support and judged at work. Although the
majority of their employers (80 percent) knew about their migraine,
only 21 percent offered support, all of which underscores the need
for better awareness and support in the workplace.2
"Migraine is a distinct neurological disease that is too often
stigmatized or overlooked in the workplace. This unique partnership
reinforces Amgen's commitment to giving individuals impacted by
migraine a voice in both their professional and personal lives,"
said Joshua J. Ofman, M.D., senior
vice president, Global Value, Access and Policy at Amgen. "We hope
this serves as a positive example for other companies and implores
them to better understand why and how they should treat migraine as
a serious disease. We believe wholeheartedly in promoting an open
and ongoing dialogue among those with migraine and their
employers."
Amgen and Piper Jordan will launch a migraine disease management
program, "Manage My Migraine," to several large employers
representing more than 50,000 employees across multiple industries.
The program consists of an educational program component as well as
a research study, which will help unlock insights around the burden
of migraine in the workplace, including its impact on absenteeism,
presenteeism, healthcare utilization and costs. The wellness
portion of the program includes five unique webinars, email tips
and a website containing disease information. The study portion of
the program includes a mobile app to track migraine symptoms that
will be analyzed.
"As an employee benefits management group that offers workplace
programs to a multitude of employers across the United States, we are delighted to be
partnering with Amgen on this initiative," said Robyn Piper, Partner at Piper Jordan. "Both
Amgen and Piper Jordan are committed to better understanding the
burden of migraine and addressing stigma in the
workplace."
Together, Amgen and Piper Jordan will use the insights gained in
this project to inform future strategy and determine how to best
disseminate the study findings to benefit those living with
migraine.
"Migraine affects millions of Americans, especially those during
their prime working years," said Lori
Johnston, senior vice president of Human Resources at Amgen.
"Although employers provide a variety of disease management
programs, rarely are programs offered specifically for people
living with migraine. We're thrilled to be partnering with Piper
Jordan to challenge public perception of migraine disease and
facilitate informed communication among people with the disease and
those who live and work with them."
Piper Jordan manages population
health programs for national, large market employers across the
U.S., representing employees across a multitude of industries.
About Migraine
People with frequent migraine may lose
more than half their life to migraine. They endure debilitating
pain, physical impairment, and live in constant dread of the next
attack – all of which is compounded by a widespread misperception
of the disease.3 The 2016 Global Burden of Disease Study
ranks migraine among the top 10 causes of years lived with
disability worldwide.4 Migraine is associated with
personal and societal burdens of pain, disability, and financial
cost, and it remains under-recognized and
under-treated.3
About Piper Jordan
Piper Jordan is a national professional services
firm devoted to delivering innovative benefit and health care
management strategies to large employers. Their health care
practice is built around the core values of controlling employer
cost without sacrificing quality. Drawing from a strong history of
analyzing complex employer and population health needs, Piper
Jordan is keenly focused on providing high-performance insights and
is dedicated to providing its full array of resources and talent
for the development of effective employer-sponsored health care
programs. For more information, visit
www.piperjordan.com.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be the world's
largest independent biotechnology company, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
Amgen and Value-Based
Programs
As a collaborative partner within the healthcare
system, Amgen believes that engaging in value-based
programs with stakeholders creates mutually beneficial
opportunities to improve costs, quality of care and the patient
experience.
Globally, Amgen is engaged in over 75 distinct,
value-based projects, spanning disease state collaborations, risk
sharing, cost-cap programs, and outcomes-based agreements. The
company has more than 25 ongoing partnerships in the United States and has several other
collaborations under development.
About Amgen and Novartis Neuroscience
Collaboration
In August 2015, Amgen entered
into a global collaboration with Novartis to develop and
commercialize pioneering treatments in the field of migraine and
Alzheimer's disease. At the center of
the Amgen and Novartis neuroscience
collaboration is the shared mission to fight migraine and the
stereotypes and misperceptions surrounding this debilitating
disease.
About the Amgen and Novartis Migraine Mission
Migraine
has gone under-appreciated and under-treated for too long. Amgen
and Novartis have committed to leading the charge together against
migraine misperceptions. Through outreach and education our goal is
to challenge public perception of migraine disease, assist people
in getting the treatment they need and facilitate informed
communication among people with migraine and those who live and
work with them, including co-workers, employers and insurers.
Future initiatives will include a focus on addressing how stigma
against migraine manifests in the workplace: migraine gets in
between people and their careers, and in between employee and
employer. We hope our workplace program will serve as an example to
coworkers, employers and human resources to help each party
understand why and how they should treat migraine as a serious
disease.
Forward Looking Statements
This news release contains
forward-looking statements that are based on the current
expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including estimates of revenues,
operating margins, capital expenditures, cash, other financial
metrics, expected legal, arbitration, political, regulatory or
clinical results or practices, customer and prescriber patterns or
practices, reimbursement activities and outcomes and other such
estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed
below and more fully described in the Securities and Exchange
Commission reports filed by Amgen, including our most
recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Unless
otherwise noted, Amgen is providing this information as
of the date of this news release and does not undertake any
obligation to update any forward-looking statements contained in
this document as a result of new information, future events or
otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and
become a commercial product. Further, preclinical results do not
guarantee safe and effective performance of product candidates in
humans. The complexity of the human body cannot be perfectly, or
sometimes, even adequately modeled by computer or cell culture
systems or animal models. The length of time that it takes for us
to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar
variability in the future. Even when clinical trials are
successful, regulatory authorities may question the sufficiency for
approval of the trial endpoints we have selected. We develop
product candidates internally and through licensing collaborations,
partnerships and joint ventures. Product candidates that are
derived from relationships may be subject to disputes between the
parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also,
we or others could identify safety, side effects or manufacturing
problems with our products, including our devices, after they are
on the market.
Our results may be affected by our ability to successfully
market both new and existing products domestically and
internationally, clinical and regulatory developments involving
current and future products, sales growth of recently launched
products, competition from other products including biosimilars,
difficulties or delays in manufacturing our products and global
economic conditions. In addition, sales of our products are
affected by pricing pressure, political and public scrutiny and
reimbursement policies imposed by third-party payers, including
governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments
and domestic and international trends toward managed care and
healthcare cost containment. Furthermore, our research, testing,
pricing, marketing and other operations are subject to extensive
regulation by domestic and foreign government regulatory
authorities. Our business may be impacted by government
investigations, litigation and product liability claims. In
addition, our business may be impacted by the adoption of new tax
legislation or exposure to additional tax liabilities. If we fail
to meet the compliance obligations in the corporate integrity
agreement between us and the U.S. government, we could become
subject to significant sanctions. Further, while we routinely
obtain patents for our products and technology, the protection
offered by our patents and patent applications may be challenged,
invalidated or circumvented by our competitors, or we may fail to
prevail in present and future intellectual property litigation. We
perform a substantial amount of our commercial manufacturing
activities at a few key facilities, including Puerto Rico, and
also depend on third parties for a portion of our manufacturing
activities, and limits on supply may constrain sales of certain of
our current products and product candidate development. In
addition, we compete with other companies with respect to many of
our marketed products as well as for the discovery and development
of new products. Further, some raw materials, medical devices and
component parts for our products are supplied by sole third-party
suppliers. Certain of our distributors, customers and payers have
substantial purchasing leverage in their dealings with us. The
discovery of significant problems with a product similar to one of
our products that implicate an entire class of products could have
a material adverse effect on sales of the affected products and on
our business and results of operations. Our efforts to acquire
other companies or products and to integrate the operations of
companies we have acquired may not be successful. A breakdown,
cyberattack or information security breach could compromise the
confidentiality, integrity and availability of our systems and our
data. Our stock price is volatile and may be affected by several
events. Our business performance could affect or limit the ability
of our Board of Directors to declare a dividend or our ability to
pay a dividend or repurchase our common stock. We may not be able
to access the capital and credit markets on terms that are
favorable to us, or at all.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Andrea Fassacesia, 805-905-2575
(media)
Arvind Sood, 805-447-1060
(investors)
References
1 Hawkins K, et al.
Indirect cost burden of migraine in the
United States. J Occup Environ Med. 2007
Apr;49(4):368-74.
2 Novartis Data on File
3 Lipton RB, et al. Migraine prevalence, disease
burden, and the need for preventative
therapy. Neurology. 2007; 68(5):343-9.
4 GBD 2016 Disease and Injury Incidence and
Prevalence Collaborators. Global, regional, and national incidence,
prevalence, and years lived with disability for 328 diseases and
injuries for 195 countries, 1990–2016: a systematic analysis for
the Global Burden of Disease Study
2016. Lancet. 2017;388:1545-1602.
View original content with
multimedia:http://www.prnewswire.com/news-releases/amgen-and-health-and-benefits-consultant-piper-jordan-partner-on-first-migraine-project-with-employers-300673456.html
SOURCE Amgen